GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (NAS:ZVRA) » Definitions » Property, Plant and Equipment

Zevra Therapeutics (Zevra Therapeutics) Property, Plant and Equipment : $1.78 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics Property, Plant and Equipment?

Zevra Therapeutics's quarterly net PPE increased from Sep. 2023 ($1.34 Mil) to Dec. 2023 ($1.53 Mil) and increased from Dec. 2023 ($1.53 Mil) to Mar. 2024 ($1.78 Mil).

Zevra Therapeutics's annual net PPE declined from Dec. 2021 ($2.03 Mil) to Dec. 2022 ($1.78 Mil) and declined from Dec. 2022 ($1.78 Mil) to Dec. 2023 ($1.53 Mil).


Zevra Therapeutics Property, Plant and Equipment Historical Data

The historical data trend for Zevra Therapeutics's Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics Property, Plant and Equipment Chart

Zevra Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Property, Plant and Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.01 2.39 2.03 1.78 1.53

Zevra Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.64 1.49 1.34 1.53 1.78

Zevra Therapeutics Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


Zevra Therapeutics  (NAS:ZVRA) Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Zevra Therapeutics Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Zevra Therapeutics (Zevra Therapeutics) Business Description

Traded in Other Exchanges
Address
1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747
Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.
Executives
Neil F. Mcfarlane director, officer: President and CEO C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
R. Laduane Clifton officer: VP Fin & Corp Controller C/O KEMPHARM, INC., 1170 CELEBRATION BLVD., #103, CELEBRATION FL 34747
Thomas Anderson director 215 FIRST STREET, CAMBRIDGE MA 02142
Joshua Schafer officer: CCO & EVP, Bus. Development SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
John B Bode director C/O TRIBUNE PUBLISHING COMPANY, 202 W. FIRST STREET, LOS ANGELES CA 90012
Watton Corey Michael director 22045 KAREN STREET, ELKHORN NE 68022
Douglas W Calder director 324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Wendy L Dixon director
Tamara A Seymour director C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Timothy J. Sangiovanni officer: VP, Corporate Controller C/O KEMPHARM, INC., 2500 CROSSPARK RD, STE E-126, CORALVILLE IA 52241
Matthew R Plooster director 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Richard W Pascoe director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Christopher Posner director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Travis C Mickle director, 10 percent owner, officer: President & CEO 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241

Zevra Therapeutics (Zevra Therapeutics) Headlines

From GuruFocus

Zevra Announces Board of Directors and Leadership Changes

By sperokesalga sperokesalga 05-08-2023